Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New alert aims to curb opioid overdoses by nudging doctors to Co-Prescribe naloxone

NCT ID NCT06271668

Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a computer alert that reminds doctors to prescribe naloxone—a drug that reverses opioid overdoses—alongside high-risk opioid prescriptions. The alert appears when a doctor orders an opioid for patients aged 12-89 (excluding those with cancer or hospice care). Researchers will compare how often naloxone is co-prescribed with and without the alert, and track overdose rates over six months. The goal is to make it easier for doctors to follow best practices and save lives.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
naloxone
What this could lead to
If successful, this alert could increase naloxone prescribing and help prevent opioid overdoses.
What could go wrong
The alert may not change doctor behavior, or patients may not fill the naloxone prescription. The study is observational, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Residents and visitors to the state of Colorado who seek healthcare within the University of Colorado Health (UCHealth) system.

Ages

12 to 89 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients receiving an opioid prescription at discharge from inpatient/ED or close visit in outpatient settings where the clinical decision support (CDS) is implemented Exclusion Criteria: * Patients \<12 and \>89 year of age * Cancer diagnosis * Hospice care/palliative care * Sickle cell disease diagnosis * Patients who arrived in error * Patients who were triaged to obstetrics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Harm reduction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute opioid poisoning Harm Reduction Opiate Overdose substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Harm reduction Medication abuse Opioid overdose Opioid prescribing

Contacts and locations

Locations

  • University of Colorado Hospital

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.